Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage pharmaceutical company headquartered in New York, New York, developing novel drug candidates for the treatment of Alzheimer's disease, Parkinson's disease, and other central nervous system disorders. The company's proprietary SIGMA1 platform has generated multiple drug candidates targeting sigma-1 receptors and muscarinic receptors[1].
Founded in 2007, Anavex has advanced its lead candidate, ANAVEX2-73 (blarcamesine), through successful Phase 2 clinical trials in Alzheimer's disease, demonstrating both cognitive benefits and disease-modifying potential[2].
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| ANAVEX2-73 (Blarcamesine) | Sigma-1 / muscarinic agonist | Alzheimer's disease | Phase 2/3 | Recruiting |
| ANAVEX3-71 | Sigma-1 agonist | Parkinson's disease | Phase 1 | Completed |
| ANAVEX1-41 | Sigma-1 agonist | Rett syndrome | Phase 2 | Clinical |
| ANAVEX19-144 | Sigma-1 agonist | Epilepsy | Preclinical | Research |
ANAVEX2-73 is a small molecule that activates both sigma-1 receptors and muscarinic receptors (M1, M3), providing a unique approach to neuroprotection:
Sigma-1 Receptor Activation:
Muscarinic Receptor Activation:
Phase 2a Study (NCT02244541):
The randomized, double-blind, placebo-controlled Phase 2a study in 32 patients with mild-to-moderate Alzheimer's disease demonstrated:
Phase 2b/3 Study (ANAVEX2-73-002):
The larger Phase 2b/3 study (n=324) confirmed:
Phase 3 (ANAVEX2-73-003):
Currently enrolling patients with early Alzheimer's disease to confirm efficacy and safety.
Anavex's SIGMA1 platform has generated multiple drug candidates:
The sigma-1 receptor is a unique chaperone protein that:
Anavex collaborates with leading academic institutions:
Headquarters: New York, New York, USA
Founded: 2007
Ticker: AVXL (NASDAQ)
CEO: Dr. Christopher U. M. Missling
Key Focus Areas:
Sigma-1 Receptor
Alzheimer's Disease Treatment
Muscarinic Receptors